424B3FORM 424B3
Aug 21, 2026Final prospectus0001437749-26-028737
All companies
424B4Aug 3, 2020
CA
Catheter Precision Inc
VTAKPublicArchived
Public / ArchivedUnited States(NYSE)1 market across 0 sources
Official IPO
Priced· NYSE· Listing market: United StatesIPO date
To be announced
Final IPO price
To be announced
Shares offered
To be announced
IPO raise
To be announced
Sources: SEC EDGAR
IPO Calendar · NYSEIPODelisted
VTAKPrice
$0.1530
24h
+0.66%
Valuation
$2.9M
24h volume
$197.14K
Type
IPO
IPO Calendar · updated Oct 5, 2026 · delisted Oct 5, 2026
Catheter Precision Inc IPO public float & lock-up
Public float and locked shares extracted from Catheter Precision Inc's SEC prospectus. Shares shown are eligible to trade — lock-up expiry does not mean holders have sold or will sell.
Total shares (FD)
48.18M
Public float
—
Locked
—
IPO raise
—
Next unlock
—
Needs review: Could not extract a detailed lock-up release schedule.
Financials
UnprofitableFrom SEC filings, latest FY ending Dec 31, 2025 · CIK 0001716621.
Revenue · +95.00% YoY
$819K
Net income
-$17.18M
Gross margin
92.31%
Cash
$88K
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $819K | $420K | $442K | $14K | $22K |
| Gross profit | $756K | $378K | $412K | -$147K | -$1.54M |
| Operating income | -$21.14M | -$11.24M | -$78.12M | -$26.96M | -$29.27M |
| Net income | -$17.18M | -$16.64M | -$70.57M | -$26.87M | -$25.07M |
| R&D expense | — | $272K | $475K | $6.39M | $12.25M |
| Cash & equivalents | $88K | $2.87M | $3.57M | $15.86M | $15.05M |
| Total assets | $15.86M | $27.77M | $30.74M | $16.84M | $21.04M |
| Total liabilities | $9.21M | $16.01M | $9.54M | $7.58M | $7.37M |
| Shareholders' equity | $7.05M | $11.76M | $21.19M | $9.26M | $13.67M |
About Catheter Precision Inc
Catheter Precision is a medical-technology company developing and selling cardiac electrophysiology products.
What the company does
- Designs technologies used by physicians treating cardiac arrhythmias and related electrophysiology conditions.
- Focuses on tools that support mapping, guidance, and procedural precision in cardiac EP workflows.
- Serves hospitals, electrophysiologists, and care teams that need specialized devices for minimally invasive heart procedures.
Business profile
Catheter Precision operates in medtech, where clinical utility, physician adoption, reimbursement, regulatory compliance, and hospital purchasing cycles drive results.
SEC IPO filings
Final prospectusEDGAR filings resolved from VTAK / CIK 0001716621.
Jul 10, 2026Effective9999999995-26-002252
424B3FORM 424B3
Jul 10, 2026Final prospectus0001437749-26-023354
S-1/AFORM S-1/A
Jul 6, 2026Amended0001437749-26-022592
S-1FORM S-1
Jun 22, 2026Filed0001437749-26-021318
May 30, 2025Effective9999999995-25-001802
424B3FORM 424B3
May 30, 2025Final prospectus0001437749-25-019020
CORRESPfilename1.htm
May 28, 2025SEC correspondence0001437749-25-018671
UPLOADfilename1.pdf
May 27, 2025SEC correspondence0000000000-25-005575
Jan 22, 2025Effective9999999995-25-000160
CORRESPfilename1.htm
Jan 17, 2025SEC correspondence0001437749-25-001386
UPLOADfilename1.pdf
Jan 16, 2025SEC correspondence0000000000-25-000481
Catheter Precision Inc IPO — frequently asked questions
- When did Catheter Precision Inc go public?
- Catheter Precision Inc has already gone public and now trades publicly on NYSE under the ticker VTAK.
- Can I buy Catheter Precision Inc stock?
- Yes — Catheter Precision Inc is publicly traded on NYSE as VTAK. You can follow its live price, valuation and post-IPO performance above.